BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the pricing of its underwritten public offering. According to the announcement, the company anticipates gross proceeds from the offering, which consists of 1,600,000 units and prefunded units, to reach an estimated $8 million. The company specified that each unit consists of one American Depositary Share (“ADS”) and two warrants; one warrant will expire three years from the date of issuance with the second warrant set to expire one year from the date of issuance. Each ADS (or prefunded warrant) is being sold with two warrants at $5 per unit. According to the company, the funds raised will be used to develop its NanoAbs program along with general corporate purposes, including working capital, R&D activities, regulatory matters, capital investment and other related purposes. Aegis Capital Corp. is acting as sole book-running manager for the offering.
To view the full press release, visit https://ibn.fm/B7W5x
About BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals, a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven-country, 12,400-participant, phase 3 trial of its prior vaccine candidate; the company has also built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nonosized antibody (“NanoAb”) pipeline. For more information about the company, please visit www.BiondVax.com
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork